Login to Your Account



Adaptimmune signs $46.5M deal for Universal Cells gene editing tech

By Michael Fitzhugh
Staff Writer

Tuesday, December 1, 2015

Adaptimmune Therapeutics plc, a U.K.-based immunotherapy developer, has agreed to pay Seattle-based start-up Universal Cells Inc. $5.5 million up front and up to $41 million in milestones for an exclusive global license to a gene editing technology that could lead to the creation of new allogeneic T-cell therapies.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription